BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 35121790)

  • 1. A systematic review and meta-analysis of the association between cyproterone acetate and intracranial meningiomas.
    Lee KS; Zhang JJY; Kirollos R; Santarius T; Nga VDW; Yeo TT
    Sci Rep; 2022 Feb; 12(1):1942. PubMed ID: 35121790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study.
    Weill A; Nguyen P; Labidi M; Cadier B; Passeri T; Duranteau L; Bernat AL; Yoldjian I; Fontanel S; Froelich S; Coste J
    BMJ; 2021 Feb; 372():n37. PubMed ID: 33536184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meningiomas and cyproterone acetate: a retrospective, monocentric cohort of 388 patients treated by surgery or radiotherapy for intracranial meningioma.
    Samarut E; Lugat A; Amelot A; Scharbarg E; Hadjadj S; Primot C; Loussouarn D; Thillays F; Buffenoir K; Cariou B; Drui D; Roualdes V
    J Neurooncol; 2021 Mar; 152(1):115-123. PubMed ID: 33392938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Presentation of a meningioma in a transwoman after nine years of cyproterone acetate and estradiol intake: case report and literature review.
    Mancini I; Rotilio A; Coati I; Seracchioli R; Martelli V; Meriggiola MC
    Gynecol Endocrinol; 2018 Jun; 34(6):456-459. PubMed ID: 29105524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preliminary report of patients with meningiomas exposed to Cyproterone Acetate, Nomegestrol Acetate and Chlormadinone Acetate - Monocentric ongoing study on progestin related meningiomas.
    Devalckeneer A; Aboukais R; Bourgeois P; De Witte O; Racape J; Caron S; Perbet R; Maurage CA; Lejeune JP
    Clin Neurol Neurosurg; 2021 Nov; 210():106959. PubMed ID: 34592677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meningioma in patients exposed to progestin drugs: results from a real-life screening program.
    Samoyeau T; Provost C; Roux A; Legrand L; Dezamis E; Plu-Bureau G; Pallud J; Oppenheim C; Benzakoun J
    J Neurooncol; 2022 Oct; 160(1):127-136. PubMed ID: 36066786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cyproterone acetate and meningioma: The latest findings].
    Schmutz JL
    Ann Dermatol Venereol; 2018 May; 145(5):390-391. PubMed ID: 29703641
    [No Abstract]   [Full Text] [Related]  

  • 8. Regression of meningiomas after discontinuation of cyproterone acetate in a transsexual patient.
    Cebula H; Pham TQ; Boyer P; Froelich S
    Acta Neurochir (Wien); 2010 Nov; 152(11):1955-6. PubMed ID: 20811919
    [No Abstract]   [Full Text] [Related]  

  • 9. Estrogen and Progesterone Therapy and Meningiomas.
    Hage M; Plesa O; Lemaire I; Raffin Sanson ML
    Endocrinology; 2022 Feb; 163(2):. PubMed ID: 34935947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormonal therapies and meningioma: is there a link?
    Cea-Soriano L; Blenk T; Wallander MA; Rodríguez LA
    Cancer Epidemiol; 2012 Apr; 36(2):198-205. PubMed ID: 21943794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of intracranial meningioma with three potent progestogens: A population-based case-control study.
    Hoisnard L; Laanani M; Passeri T; Duranteau L; Coste J; Zureik M; Froelich S; Weill A
    Eur J Neurol; 2022 Sep; 29(9):2801-2809. PubMed ID: 35621369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abrupt regression of a meningioma after discontinuation of cyproterone treatment.
    Gonçalves AM; Page P; Domigo V; Méder JF; Oppenheim C
    AJNR Am J Neuroradiol; 2010 Sep; 31(8):1504-5. PubMed ID: 20053802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical evolution of meningiomatosis after discontinuation of cyproterone acetate: clinical cases and histomolecular characterization.
    Passeri T; Giammattei L; Le Van T; Abbritti R; Perrier A; Wong J; Bourneix C; Polivka M; Adle-Biassette H; Bernat AL; Masliah-Planchon J; Mandonnet E; Froelich S
    Acta Neurochir (Wien); 2022 Jan; 164(1):255-263. PubMed ID: 34613529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyproterone acetate and risk of meningioma: a nationwide cohort study.
    Mikkelsen AP; Greiber IK; Scheller NM; Hilden M; Lidegaard Ø
    J Neurol Neurosurg Psychiatry; 2022 Feb; 93(2):222-223. PubMed ID: 34187864
    [No Abstract]   [Full Text] [Related]  

  • 15. Combined hormonal influence of cyproterone acetate and nomegestrol acetate on meningioma: a case report.
    Champagne PO; Passeri T; Froelich S
    Acta Neurochir (Wien); 2019 Mar; 161(3):589-592. PubMed ID: 30666456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of meningioma among users of high doses of cyproterone acetate as compared with the general population: evidence from a population-based cohort study.
    Gil M; Oliva B; Timoner J; Maciá MA; Bryant V; de Abajo FJ
    Br J Clin Pharmacol; 2011 Dec; 72(6):965-8. PubMed ID: 21627676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth of a meningioma in a transsexual patient after estrogen-progestin therapy.
    Gazzeri R; Galarza M; Gazzeri G
    N Engl J Med; 2007 Dec; 357(23):2411-2. PubMed ID: 18057351
    [No Abstract]   [Full Text] [Related]  

  • 18. First case of cyproterone acetate induced multiple meningiomas in identical female twins: A case report.
    Batchinsky-Parrou V; Barraud S; Kleiber JC; Litre F
    Neurochirurgie; 2022 Apr; 68(3):323-326. PubMed ID: 33989640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Probable Drug-Related Meningioma Detected During the Course of Medication Review Services.
    Alderman CP
    Consult Pharm; 2016 Sep; 31(9):500-4. PubMed ID: 27636874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiological evolution of progestogen-induced meningioma: A monocentric retrospective study.
    Ahmed-Khalifa T; Gillet R; Blonski M; Rech F; Fresse A; Gillet P; Taillandier L; Petitpain N
    Fundam Clin Pharmacol; 2023 Aug; 37(4):868-878. PubMed ID: 36692232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.